Humacyte’s (HUMA) “Buy” Rating Reaffirmed at Benchmark

Benchmark reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Monday, Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Separately, HC Wainwright initiated coverage on shares of Humacyte in a research note on Monday, December 11th. They issued a buy rating and a $6.00 price objective on the stock.

Humacyte Trading Up 0.3 %

Shares of Humacyte stock opened at $3.11 on Monday. The company has a current ratio of 6.79, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. Humacyte has a 12-month low of $1.96 and a 12-month high of $5.60. The firm has a market capitalization of $363.43 million, a price-to-earnings ratio of -2.91 and a beta of 1.53. The firm’s 50 day simple moving average is $3.55 and its two-hundred day simple moving average is $2.98.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter last year, the business posted ($0.21) EPS. Analysts predict that Humacyte will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Holdings Inc. lifted its stake in shares of Humacyte by 24.6% in the first quarter. Advisor Group Holdings Inc. now owns 25,020 shares of the company’s stock worth $177,000 after buying an additional 4,946 shares in the last quarter. Swiss National Bank increased its position in Humacyte by 7.4% during the first quarter. Swiss National Bank now owns 121,800 shares of the company’s stock worth $860,000 after purchasing an additional 8,400 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Humacyte during the first quarter worth about $188,000. Citigroup Inc. increased its position in Humacyte by 191.7% during the first quarter. Citigroup Inc. now owns 11,859 shares of the company’s stock worth $84,000 after purchasing an additional 7,793 shares during the last quarter. Finally, BlackRock Inc. increased its position in Humacyte by 12.6% during the first quarter. BlackRock Inc. now owns 1,577,919 shares of the company’s stock worth $11,140,000 after purchasing an additional 176,846 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).